ESSA Pharma Narrows Losses Amid R&D Cuts, Strategic Shift

TL;DR

**ESSA Pharma is winding down its core R&D, signaling a potential liquidation or major strategic pivot, so get out now if you're not in for the long, uncertain haul.**

AI Summary

ESSA Pharma Inc. reported a net loss of $18,909,992 for the nine months ended June 30, 2025, a 14.86% improvement from the $22,187,604 net loss in the prior year period. Research and development expenses significantly decreased by 50.49% to $8,427,148 from $17,018,874, primarily due to the discontinuation of masofaniten development. Conversely, general and administration expenses rose by 39.44% to $13,536,542 from $9,707,565. The company's cash and cash equivalents declined to $85,952,587 as of June 30, 2025, from $103,709,537 at September 30, 2024, reflecting net cash used in operating activities of $17,518,819. Total assets decreased to $110,502,100 from $128,112,003 over the same period. The company also incurred a loss on termination of lease of $145,220. Strategic outlook includes a potential 'Transaction' and 'Liquidation Resolution,' indicating a significant shift in business model.

Why It Matters

This 10-Q signals a critical juncture for ESSA Pharma, as the significant reduction in R&D spending and the mention of a 'Transaction' and 'Liquidation Resolution' suggest a pivot away from its previous drug development focus. For investors, this could mean a return of capital or a new strategic direction, but also highlights the inherent risks in biotech R&D. Employees face uncertainty given the discontinuation of masofaniten development and potential workforce reductions. Customers, specifically patients awaiting masofaniten, will be impacted by the cessation of its development. Competitively, this move could open space for rivals in the prostate cancer treatment landscape, while also reflecting broader industry pressures on smaller biotechs to achieve profitability or find strategic alternatives.

Risk Assessment

Risk Level: high — The risk level is high due to the discontinuation of masofaniten development, which was a key product candidate, and explicit mentions of a 'Transaction' and 'Liquidation Resolution' requiring shareholder approval. The company's cash and cash equivalents decreased by $17,756,950 in the nine months ended June 30, 2025, and it continues to incur significant losses, with an accumulated deficit of $226,914,172.

Analyst Insight

Investors should closely monitor the upcoming shareholder votes on the 'Liquidation Resolution' and 'Liquidator Resolution' and any details regarding the 'Transaction.' Given the significant strategic shift and potential for liquidation, a cautious approach is warranted. Consider reducing exposure if the liquidation path is confirmed, or await clear details on any new strategic direction before making further investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

$110,502,100

total Debt

N/A

net Income

-$18,909,992

eps

N/A

gross Margin

N/A

cash Position

$85,952,587

revenue Growth

N/A

Key Numbers

• $18,909,992 — Net loss for nine months ended June 30, 2025 (14.86% improvement from prior year)
• $8,427,148 — Research and development expenses (50.49% decrease year-over-year)
• $13,536,542 — General and administration expenses (39.44% increase year-over-year)
• $85,952,587 — Cash and cash equivalents (as of June 30, 2025, down from $103,709,537)
• $17,518,819 — Net cash used in operating activities (for the nine months ended June 30, 2025)
• $110,502,100 — Total assets (as of June 30, 2025, down from $128,112,003)
• $226,914,172 — Accumulated deficit (as of June 30, 2025, indicating significant historical losses)
• 47,308,394 — Outstanding Common Shares (as of August 13, 2025)

Key Players & Entities

• ESSA Pharma Inc. (company) — registrant
• masofaniten (product) — discontinued drug development
• Jefferies LLC (company) — partner for ATM Sales Agreement
• Cancer Prevention and Research Institute of Texas (company) — grant provider (CPRIT)
• Nasdaq Capital Market (regulator) — exchange where common shares are registered
• SEC (regulator) — filing oversight

FAQ

Risk Factors

• Discontinuation of Masofaniten Development [medium — operational]: The company significantly reduced R&D expenses by 50.49% to $8,427,148 for the nine months ended June 30, 2025, primarily due to the discontinuation of masofaniten development. This strategic shift indicates a change in the company's research focus and potential pipeline adjustments.
• Increased General and Administration Expenses [medium — financial]: General and administration expenses increased by 39.44% to $13,536,542 for the nine months ended June 30, 2025. This rise, despite a decrease in R&D, contributes to the overall net loss and warrants scrutiny into operational spending.
• Declining Cash Position and Operating Cash Burn [high — financial]: Cash and cash equivalents decreased to $85,952,587 as of June 30, 2025, from $103,709,537 at September 30, 2024. The company used $17,518,819 in net cash from operating activities during the nine months ended June 30, 2025, indicating a substantial burn rate.
• Accumulated Deficit [high — financial]: The company has an accumulated deficit of $226,914,172 as of June 30, 2025. This substantial historical loss highlights the long-term financial challenges and the need for future profitability or funding.
• Potential 'Transaction' and 'Liquidation Resolution' [high — operational]: The strategic outlook mentions a potential 'Transaction' and 'Liquidation Resolution.' These terms suggest a significant shift in the company's business model, potentially involving asset sales, mergers, or dissolution, which introduces considerable uncertainty.
• Loss on Termination of Lease [low — financial]: The company incurred a loss of $145,220 on the termination of a lease during the period. While not a primary driver of the overall loss, it indicates restructuring activities and associated costs.

Industry Context

ESSA Pharma operates in the biotechnology sector, which is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. The industry is competitive, with companies often focusing on specific therapeutic areas. Recent trends include strategic partnerships, mergers, and acquisitions as companies seek to advance their pipelines or achieve economies of scale.

Regulatory Implications

As a biotechnology company, ESSA Pharma is subject to stringent regulatory oversight from bodies like the FDA. Changes in R&D focus, such as discontinuing a drug candidate, can have implications for future regulatory submissions and approvals. The company's potential 'Transaction' or 'Liquidation Resolution' may also involve regulatory considerations depending on the nature of the event.

What Investors Should Do

1. Monitor cash burn and runway.
2. Analyze the implications of the 'Transaction' or 'Liquidation Resolution'.
3. Scrutinize the increase in G&A expenses.

Key Dates

• 2025-06-30: Nine months ended June 30, 2025 — Reporting period showing a net loss of $18,909,992, with significant R&D cost reduction and increased G&A expenses.
• 2024-09-30: September 30, 2024 — Balance sheet date showing cash and cash equivalents of $103,709,537 and total assets of $128,112,003.

Glossary

Accumulated deficit

The total net losses of a company that have not been offset by profits since its inception. (Indicates the company's history of net losses, standing at $226,914,172 as of June 30, 2025.)

Operating lease right-of-use asset

An asset recognized under accounting standards for the right to use an asset for the lease term. (This asset was $295,471 as of September 30, 2024, and is $0 as of June 30, 2025, indicating lease terminations.)

Loss on termination of lease

A charge recognized when a lease agreement is ended before its scheduled expiration. (The company recorded a $145,220 loss from lease termination, reflecting operational changes.)

Masofaniten

A specific drug candidate or development program. (The discontinuation of its development was a primary driver for the significant decrease in R&D expenses.)

Year-Over-Year Comparison

Compared to the prior year period, ESSA Pharma Inc. reported a reduced net loss of $18,909,992 for the nine months ended June 30, 2025, a 14.86% improvement. This was largely driven by a 50.49% decrease in R&D expenses due to discontinued development, while general and administration expenses saw a significant increase of 39.44%. The company's cash position has declined, and total assets have decreased, reflecting ongoing operational cash burn and strategic adjustments.

Filing Documents

• epix-20250630x10q.htm (10-Q) — 1391KB
• epix-20250630xex31d1.htm (EX-31.1) — 7KB
• epix-20250630xex31d2.htm (EX-31.2) — 7KB
• epix-20250630xex32d1.htm (EX-32.1) — 9KB
• epix-20250630x10q001.jpg (GRAPHIC) — 17KB
• epix-20250630x10q003.jpg (GRAPHIC) — 37KB
• epix-20250630x10q004.jpg (GRAPHIC) — 37KB
• 0001558370-25-011295.txt ( ) — 4982KB
• epix-20250630.xsd (EX-101.SCH) — 34KB
• epix-20250630_cal.xml (EX-101.CAL) — 32KB
• epix-20250630_def.xml (EX-101.DEF) — 100KB
• epix-20250630_lab.xml (EX-101.LAB) — 278KB
• epix-20250630_pre.xml (EX-101.PRE) — 198KB
• epix-20250630x10q_htm.xml (XML) — 699KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION 7 Item 1.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 7 Condensed Consolidated Interim Balance Sheets as of June 30, 2025 and September 30, 2024 8 Condensed Consolidated Interim Statements of Operations and Comprehensive Loss for the three and nine months ended June 30, 2025 and 2024 9 Condensed Consolidated Interim Statements of Cash Flows for the nine months ended June 30, 2025 and 2024 10 Condensed Consolidated Interim Statement of Changes in Shareholders' Equity for the three and nine months ended June 30, 2025 and 2024 11 Notes to the Condensed Consolidated Interim Financial Statements 12 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 21 Item 3. Quantitative and Qualitative Disclosure About Market Risk 46 Item 4.

Controls and Procedures

Controls and Procedures 46

OTHER INFORMATION

PART II. OTHER INFORMATION 47 Item 1.

Legal Proceedings

Legal Proceedings 47 Item 1A.

Risk Factors

Risk Factors 47 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 47 Item 3. Defaults Upon Senior Securities 48 Item 4. Mine Safety Disclosures 48 Item 5. Other Information 48 Item 6. Exhibits, Financial Statement Schedules 49

SIGNATURES

SIGNATURES 50 2 Table of Contents CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q includes "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements include statements that may relate to our plans, objectives, goals, strategies, future events, future revenue or performance, capital expenditures, financing needs and other information that is not historical information. Many of these statements appear, in particular, under the headings "Business," "Risk Factors," and "Management's Discussion and Analysis of Financial Condition and Results of Operations." Forward-looking statements can often be identified by the use of terminology such as "subject to," "believe," "anticipate," "plan," "expect," "intend," "estimate," "project," "may," "might," "will," "should," "would," "could," "hope," "can," the negatives thereof, variations thereon and similar expressions, or by discussions of strategy. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements. Examples of such forward looking statements include, but are not limited to statements related to: the Transaction, including financial estimates and statements as to the expected timing, completion and effects of the Transaction (as defined below); shareholder approval of the Liquidation Resolution (as defined below); shareholder approval of the Liquidator Resolution (as defined below); the Company's intention to apply to the court for the appointment of a liquidator in the event the Liquidation Resolution and Liquidat

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements and Supplementary Data

Item 1. Financial Statements and Supplementary Data ESSA Pharma Inc. CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS (Unaudited) (Expressed in United States dollars) FOR THE THREE AND NINE MONTHS ENDED JUNE 30, 2025 7 Table of Contents ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM BALANCE SHEETS (Unaudited) (Expressed in United States dollars) AS OF June 30, September 30, 2025 2024 ASSETS Current Cash and cash equivalents $ 85,952,587 $ 103,709,537 Short-term investments (Note 4) 23,667,161 23,050,582 Receivables 527,148 162,973 Prepaids (Note 5) 355,204 636,463 110,502,100 127,559,555 Deposits — 256,977 Operating lease right-of-use asset (Note 7) — 295,471 Total assets $ 110,502,100 $ 128,112,003 LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities (Note 6) $ 1,599,955 $ 3,176,973 Current portion of operating lease liability (Note 7) — 124,054 1,599,955 3,301,027 Operating lease liability (Note 7) — 205,206 Total liabilities 1,599,955 3,506,233 Shareholders' equity Authorized Unlimited common shares, without par value Unlimited preferred shares, without par value Common shares 44,388,550 issued and outstanding (September 30, 2024 – 44,388,550 ) (Note 8) 279,862,420 279,862,420 Additional paid-in capital (Note 8) 58,050,904 54,810,797 Accumulated other comprehensive loss ( 2,097,007 ) ( 2,063,267 ) Accumulated deficit ( 226,914,172 ) ( 208,004,180 ) 108,902,145 124,605,770 Total liabilities and shareholders' equity $ 110,502,100 $ 128,112,003 Nature of operations (Note 1) Contingent Liability (Note 12) Subsequent Events (Notes 8 and 13) The accompanying notes are an integral part of these condensed consolidated interim financial statements. 8 Table of Contents ESSA PHARMA INC. CONDENSED CONSOLIDATED INTERIM STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) (Expressed in Un

View Full Filing

View this 10-Q filing on SEC EDGAR